Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study to Assess the Safety and Activity of DURvalumab (MEDI4736) in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr

NCT04106115 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT04106115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04106115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study to Assess the Safety and Activity of DURvalumab (MEDI4736) in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr
Lead sponsor
University College, London
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 25, 2022
Completion date
September 30, 2032
Enrollment
52 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer